Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin

Overview

Journal Clin Pharmacol Ther

Publisher Wiley

Specialty Pharmacology

Date 2016 Jun 4

PMID 27256812

Citations 29

Authors

P Stopfer

T Giessmann

K Hohl

A Sharma

N Ishiguro

M E Taub

H Zimdahl-Gelling

D Gansser

M Wein

T Ebner

F Muller

Affiliations

Soon will be listed here.

Abstract

This article reports the clinical investigation of a probe drug cocktail containing substrates of key drug transporters. Single oral doses of 0.25 mg digoxin (P-gp), 5 mg furosemide (OAT1 and OAT3), 500 mg metformin (OCT2, MATE1, and MATE2-K), and 10 mg rosuvastatin (OATP1B1, OATP1B3, and BCRP) were administered separately or as a cocktail in a randomized six-period crossover trial in 24 healthy male volunteers. As a cocktail, relative bioavailabilities of digoxin and metformin and furosemide AUC0-tz were similar to separate dosing. However, when administered as a cocktail the Cmax of furosemide was 19.1% lower and the Cmax and AUC0-tz of rosuvastatin were 38.6% and 43.4% higher, respectively. In addition, the effects of increased doses of metformin or furosemide on the cocktail were investigated in 11 and 12 subjects, respectively. The cocktail explored in this trial has the potential to be used for the in vivo screening of transporter-mediated drug-drug interactions. © 2016 American Society for Clinical Pharmacology and Therapeutics.

Citing Articles

Innovative Approaches to Optimize Clinical Transporter Drug-Drug Interaction Studies.

Paglialunga S, Benrimoh N, van Haarst A Pharmaceutics. 2024; 16(8).

PMID: 39204337 PMC: 11359485. DOI: 10.3390/pharmaceutics16080992.

Effect of midostaurin on the pharmacokinetics of P-gp, BCRP, and CYP2D6 substrates: assessing potential drug-drug interactions in healthy participants : Brief title: Drug-drug interaction of midostaurin.

Sechaud R, Gu H, Rahmanzadeh G, Chiparus O, Breitschaft A, Menssen H Cancer Chemother Pharmacol. 2024; 94(4):535-547.

PMID: 39110203 DOI: 10.1007/s00280-024-04683-3.

Liver Fibrosis Stages Affect Organic Cation Transporter 1/2 Activities in Hepatitis C Virus-Infected Patients.

Thomaz M, Vieira C, Caris J, Marques M, Rocha A, Paz T Pharmaceuticals (Basel). 2024; 17(7).

PMID: 39065716 PMC: 11280093. DOI: 10.3390/ph17070865.

Clinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration.

Piscitelli J, Reddy M, Wollenberg L, Del Frari L, Gong J, Wood L Clin Pharmacokinet. 2024; 63(4):483-496.

PMID: 38424308 PMC: 11052825. DOI: 10.1007/s40262-024-01352-9.

The Impact of Inflammation on the In Vivo Activity of the Renal Transporters OAT1/3 in Pregnant Women Diagnosed with Acute Pyelonephritis.

Benzi J, Dos Santos Melli P, Duarte G, Unadkat J, Lanchote V Pharmaceutics. 2023; 15(10).

PMID: 37896187 PMC: 10610490. DOI: 10.3390/pharmaceutics15102427.

References

Lou X, Zhang W, Wang G, Hu D, Guo D, Tan Z . The effect of Na+/taurocholate cotransporting polypeptide (NTCP) c.800C > T polymorphism on rosuvastatin pharmacokinetics in Chinese healthy males. Pharmazie. 2015; 69(10):775-9. View

Brown D, Dormois J, Abraham G, Lewis K, Dixon K . Effect of furosemide on the renal excretion of digoxin. Clin Pharmacol Ther. 1976; 20(4):395-400. DOI: 10.1002/cpt1976204395. View

Giacomini K, Huang S, Tweedie D, Benet L, Brouwer K, Chu X . Membrane transporters in drug development. Nat Rev Drug Discov. 2010; 9(3):215-36. PMC: 3326076. DOI: 10.1038/nrd3028. View

Hillgren K, Keppler D, Zur A, Giacomini K, Stieger B, Cass C . Emerging transporters of clinical importance: an update from the International Transporter Consortium. Clin Pharmacol Ther. 2013; 94(1):52-63. DOI: 10.1038/clpt.2013.74. View

Smith D, Gee W, Brater D, Lin E, Benet L . Preliminary evaluation of furosemide-probenecid interaction in humans. J Pharm Sci. 1980; 69(5):571-5. DOI: 10.1002/jps.2600690526. View

Elsby R, Hilgendorf C, Fenner K . Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1. Clin Pharmacol Ther. 2012; 92(5):584-98. DOI: 10.1038/clpt.2012.163. View

Gibson T, Quintanilla A . Effect of volume expansion and furosemide diuresis on the renal clearance of digoxin. J Pharmacol Exp Ther. 1981; 219(1):54-9. View

Neuvonen P, Niemi M, Backman J . Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006; 80(6):565-81. DOI: 10.1016/j.clpt.2006.09.003. View

Zolk O, Fromm M . Transporter-mediated drug uptake and efflux: important determinants of adverse drug reactions. Clin Pharmacol Ther. 2011; 89(6):798-805. DOI: 10.1038/clpt.2010.354. View

10.

McAllister Jr R, Howell S, Gomer M, Selby J . Effect of intravenous furosemide on the renal excretion of digoxin. J Clin Pharmacol. 1976; 16(2-3):110-7. DOI: 10.1002/j.1552-4604.1976.tb02391.x. View

11.

Lee D, Roh H, Son H, Jang S, Lee S, Nam S . Pharmacokinetic interaction between rosuvastatin and metformin in healthy Korean male volunteers: a randomized, open-label, 3-period, crossover, multiple-dose study. Clin Ther. 2014; 36(8):1171-81. DOI: 10.1016/j.clinthera.2014.06.004. View

12.

Abe K, Bridges A, Yue W, Brouwer K . In vitro biliary clearance of angiotensin II receptor blockers and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in sandwich-cultured rat hepatocytes: comparison with in vivo biliary clearance. J Pharmacol Exp Ther. 2008; 326(3):983-90. PMC: 2581923. DOI: 10.1124/jpet.108.138073. View

13.

Bosgra S, van de Steeg E, Vlaming M, Verhoeckx K, Huisman M, Verwei M . Predicting carrier-mediated hepatic disposition of rosuvastatin in man by scaling from individual transfected cell-lines in vitro using absolute transporter protein quantification and PBPK modeling. Eur J Pharm Sci. 2014; 65:156-66. DOI: 10.1016/j.ejps.2014.09.007. View

14.

Prueksaritanont T, Chu X, Evers R, Klopfer S, Caro L, Kothare P . Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin. Br J Clin Pharmacol. 2014; 78(3):587-98. PMC: 4243909. DOI: 10.1111/bcp.12377. View

15.

Naafs M, Van der Hoek C, SCHOPMAN W, van Duin S, Koorevaar G, Silberbusch J . Renal clearance of digoxin in man after sodium loading or furosemide treatment. Eur J Clin Pharmacol. 1983; 25(3):375-9. DOI: 10.1007/BF01037951. View

16.

Streetman D, Bleakley J, Kim J, Nafziger A, Leeder J, Gaedigk A . Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail". Clin Pharmacol Ther. 2000; 68(4):375-83. DOI: 10.1067/mcp.2000.109519. View

17.

Muller F, Fromm M . Transporter-mediated drug-drug interactions. Pharmacogenomics. 2011; 12(7):1017-37. DOI: 10.2217/pgs.11.44. View

18.

TSUTSUMI E, Fujiki H, Takeda H, Fukushima H . Effect of furosemide on serum clearance and renal excretion of digoxin. J Clin Pharmacol. 1979; 19(4):200-4. DOI: 10.1002/j.1552-4604.1979.tb01652.x. View

19.

Somogyi A, Stockley C, Keal J, Rolan P, Bochner F . Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol. 1987; 23(5):545-51. PMC: 1386190. DOI: 10.1111/j.1365-2125.1987.tb03090.x. View

20.

Tilstone W, Semple P, Lawson D, Boyle J . Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin. Clin Pharmacol Ther. 1977; 22(4):389-94. DOI: 10.1002/cpt1977224389. View